The impact of sirolimus on hepatitis C recurrence after liver transplantation

Canadian Journal of Gastroenterology

Volumn 25, Issue 1, 2011, Pages 28-34

  Asthana, Sonal ^a   Toso, Christian ^a   Meeberg, Glenda ^a   Bigam, David L ^a   Mason, Andrew ^a   Shapiro, James ^a   Kneteman, Norman M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Hepatitis C; Immunosuppression; Liver transplantation; Recurrence; Sirolimus

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; COLD ISCHEMIA; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; STEROID THERAPY; SURVIVAL; DISEASE COURSE; DRUG ANTAGONISM; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; VIROLOGY;

ADULT; AGED; CALCINEURIN; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 79952265424     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/201019     Document Type: Article

References (29)

1. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9.
2. Feray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992;89:1361-5.
3. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-22.
4. Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-43. (Pubitemid 24323557)
5. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-77. (Pubitemid 26021616)
6. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: Persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000;6:44-53. (Pubitemid 30123367)
7. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-84. (Pubitemid 30180389)
8. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9(Suppl):1-9.
9. Samonakis DN, Cholongitas E, Triantos CK, et al. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005;43:1091-3. (Pubitemid 41627997)
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93. (Pubitemid 26260021)
11. Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: Reassessment of risk factors for tumor recurrence. Ann Surg 2008;248:857-62.
12. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007;13:719-24. (Pubitemid 46804363)
13. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-22.
14. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis. Liver Transpl 2007;13:21-9. (Pubitemid 46099970)
15. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12:51-7.
16. Watashi K, Hijikata M, Hosaka M, Yamagi M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-8. (Pubitemid 37314838)
17. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-41. (Pubitemid 41242693)
18. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus vs. cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis C: A prospective randomized trial. Liver Transpl 2004;10:1258-62. (Pubitemid 39406080)
19. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41. (Pubitemid 36775793)
20. Gedaly R, Clifford TM, McHugh PP, Jeon H, Johnston TD, Ranjan D. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: Results of a multi-center international survey. Transpl Int 2008;21:867-72.
21. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003;35(Suppl 3):193S-200S. (Pubitemid 36547944)
22. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation 2007;83:1162-8. (Pubitemid 46743675)
23. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10:1301-11. (Pubitemid 39406087)
24. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010;51:1237-43.
25. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006;45:786-96. (Pubitemid 44646687)
26. Heuer M, Benkö T, Cicinnati VR, et al. Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines. Transplant Proc 2009;41:359-65.
27. Pelletier SJ, Schaubel DE, Wei G, et al. Effect of body mass index on the survival benefit of liver transplantation. Liver Transpl 2007;13:1678-83.
28. Lietz K, John R, Burke EA, et al. Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. Transplantation 2001;72:277-83. (Pubitemid 32729349)
29. Berenguer M, Aguilera V, Martín Prieto, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006;12:762-7.